Results
A total of 6,180 patients had at least one visit to one of the HFCs during the randomization period, of which 1,640 fulfilled the criteria for stability and were eligible (After 5 years of follow-up, 335 (72.7%) patients in the HFC group and 325 (70.7%) patients in the PC group were still alive. At 5 years following randomization, 64 (19.1%) and 62 (19.1%) patients had an implantable cardioverter-defibrillator in the HFC and PC group, respectively (chisq test p-value = 1.00), and 25 (7.5%) and 30 (9.2%) patients had a cardiac resynchronization therapy device in the HFC and PC group, respectively (chisq test p-value = 0.50).